Quercetin Promotes Abdominal Aortic Aneurysm Regression Through the RAGE/PI3K/AKT/mTOR Axis

被引:0
|
作者
Yang, Xin [1 ]
Wang, Ying [1 ]
Xin, Guangyu [1 ]
Li, Jie [1 ]
Xu, Lei [1 ]
Zhang, Guohua [2 ]
Yang, Haotian [2 ]
机构
[1] Qiqihar Med Univ, Affiliated Hosp 2, Qiqihar 161006, Peoples R China
[2] Heilongjiang Acad Agr Sci, Branch Anim Husb & Vet Branch, Qiqihar, Peoples R China
关键词
quercetin; RAGE; abdominal aortic aneurysm; elastase; RAGE/PI3K/AKT/mTOR; SUPPRESSES; THERAPY; CANCER; RAGE;
D O I
10.1177/1934578X241286438
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: Abdominal aortic aneurysms (AAA) are a common critical cardiovascular disease with high morbidity and mortality rates. Quercetin, a flavonoid and a traditional Chinese medicinal ingredient commonly found in vegetables and fruits, has a favorable inhibitory effect on experimental aneurysms without side effects. This study aimed to model elastase AAA and investigate the mechanism of action of quercetin in alleviating AAA. Methods: Quercetin was administered at a dose of 60 mg/kg once daily starting on the day of AAA induction for 5 weeks. The therapeutic effect of quercetin on AAA was demonstrated using biochemical assays, observation of pathological tissue sections, Elastic Van Gieson staining, immunohistochemistry, molecular docking simulations, and Western blot protein validation. Results: Our study showed that quercetin treatment significantly alleviated abdominal aortic vessel wall dilatation, elastin degradation and adhesion to surrounding tissues caused by elastase. Additionally, quercetin significantly inhibited the mRNA and protein expression of the receptor for advanced glycation end products(RAGE)/ phosphatidylinositol 3-kinase (PI3K)/ phosphatidylinositol 3-kinase (AKT) / mammlian target of rapamycin (mTOR) pathway. Conclusion: Quercetin can alleviate abdominal aortic injury caused by elastase via RAGE/PI3K/AKT/mTOR and provide experience in clinical use.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells
    Lan, Chieh-Yu
    Chen, Sheng-Yi
    Kuo, Chia-Wen
    Lu, Chi-Cheng
    Yen, Gow-Chin
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2019, 27 (04) : 887 - 896
  • [2] FGF21 promotes angiotensin II-induced abdominal aortic aneurysm via PI3K/AKT/mTOR pathway
    Gu, Xuefeng
    Li, Qi
    Qian, Tianwei
    Hu, Qi
    Gu, Jianfeng
    Ding, Wei
    Li, Ming
    Wang, Ming
    Lu, Huan
    Tao, Ke
    VASCULAR, 2024, 32 (06) : 1369 - 1377
  • [3] Oncogenic Roles of the PI3K/AKT/mTOR Axis
    Aoki, Masahiro
    Fujishita, Teruaki
    VIRUSES, GENES, AND CANCER, 2017, 407 : 153 - 189
  • [4] PIK3CB promotes oesophageal cancer proliferation through the PI3K/AKT/mTOR signalling axis
    Xu, Wei
    Wang, Zhiqiang
    Zhang, Zhi
    Xu, Jian
    Jiang, Yuequan
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (09) : 1399 - 1408
  • [5] PI3K/AKT/mTOR
    Umemura, Shigeki
    Goto, Koichi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117
  • [6] Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
    Ratti, Stefano
    Mauro, Raffaella
    Rocchi, Cristina
    Mongiorgi, Sara
    Ramazzotti, Giulia
    Gargiulo, Mauro
    Manzoli, Lucia
    Cocco, Lucio
    Fiume, Roberta
    BIOMOLECULES, 2022, 12 (03)
  • [7] Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
    Yeh, Tzu-Shao
    Hsu, Cheng-Chen
    Yang, Suh-Ching
    Hsu, Mei-Chich
    Liu, Jen-Fang
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14
  • [8] Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
    Tzu-Shao Yeh
    Cheng-Chen Hsu
    Suh-Ching Yang
    Mei-Chich Hsu
    Jen-Fang Liu
    BMC Complementary and Alternative Medicine, 14
  • [9] Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
    Blachly, James S.
    Baiocchi, Robert A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) : 19 - 32
  • [10] Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
    Tong, Xin
    Pelling, Jill C.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 971 - 978